Loading...

China NT Pharma Group Company Limited

1011.HKHKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$0.42
HK$0.02(5.00%)

China NT Pharma Group Company Limited 1011.HK Peers

See (1011.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1011.HKHK$0.42+5.00%283.2M-1.91-HK$0.22N/A
3692.HKHK$29.75+2.23%176.9B37.19HK$0.80N/A
2196.HKHK$16.88+4.07%68.3B14.07HK$1.20+1.78%
0874.HKHK$17.40+0.00%43.8B9.61HK$1.81+5.05%
1513.HKHK$29.55+0.68%32.8B11.73HK$2.52+4.06%
3320.HKHK$5.12-1.35%32.2B8.83HK$0.58+2.87%
0512.HKHK$8.72+1.04%30.5B12.46HK$0.70+2.98%
0867.HKHK$12.00+0.00%29B16.44HK$0.73+2.43%
3933.HKHK$15.02+1.08%27.3B9.39HK$1.60+4.10%
0013.HKHK$23.55-0.84%20.5B75.97HK$0.31N/A
Showing 1 to 10 of 42 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1011.HK vs 3692.HK Comparison

1011.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1011.HK stands at 283.2M. In comparison, 3692.HK has a market cap of 176.9B. Regarding current trading prices, 1011.HK is priced at HK$0.42, while 3692.HK trades at HK$29.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1011.HK currently has a P/E ratio of -1.91, whereas 3692.HK's P/E ratio is 37.19. In terms of profitability, 1011.HK's ROE is +0.14%, compared to 3692.HK's ROE of +0.15%. Regarding short-term risk, 1011.HK is less volatile compared to 3692.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1011.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;